ArticleMolecular therapy. Methods & clinical development2019

Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1.

Shilpa Prabhakar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.